Early Access — free while we kick the tires
EdgarHawk

Silvercape Investments Ltd

10% Owner

10% Owner
7 filings analyzed · 1 company · Latest 2025-08-14

Companies

Company Buys Sells Direction
PETMED EXPRESS INC PETS 7 0 Net buying

Activity

August 2025
2025-08-14 PETMED EXPRESS INC PETS
medium
Buy
101,000 shares
$320,170
Significance 4/10

10% owner Silvercape Investments buys 101,000 shares of PETS at $3.17 after recent similar purchases; stock -53.0% from 52-week high

Silvercape Investments, a 10% owner, purchased 101,000 shares at $3.17 on 2025-08-13, adding to a pattern of five prior purchases at PETS within the preceding six weeks (2025-07-01 through 2025-08-01). The current price of $3.10 is down -53.0% from the 52-week high of $6.60, and the stock has declined -19.7% over the past 90 days. PETS reports -$707,000 net income on $53.0M quarterly revenue, with a trailing P/E of 155 and a market cap of $64.0M, indicating the company remains unprofitable on a full-year basis despite +9.4% revenue growth. The repeated accumulation at depressed prices—now at $3.17 following buys at $3.02 and lower on prior dates—warrants examination of whether this reflects conviction in a turnaround or mechanical accumulation within a pre-established plan.

2025-08-04 PETMED EXPRESS INC PETS
medium
Buy
118,200 shares
$379,422
Significance 4/10

10% owner Silvercape Investments Ltd bought 118,200 shares of PETS at $3.21 on 2025-08-01; stock down -51.5% from 52-week high of $6.60.

Silvercape Investments Ltd, a 10% owner, purchased 118,200 shares (raising holdings by +5.0% to 2.48M shares) at $3.21, bringing total transaction value to $379,422.00. The stock is currently trading at $3.20, having declined -51.5% from its 52-week high of $6.60 and fallen -9.6% over the past 90 days. The company reported revenue of $53.0M in its latest quarter but remains unprofitable with a net loss of $-707.0K, warranting scrutiny given the elevated P/E ratio of 160.00. Reviewing Silvercape's prior trades at PETS, five recent buys (spanning 2025-05-20 through 2025-07-18) have shown mixed results: a buy on 2025-07-02 returned +0.6% at 30 days, while a buy on 2025-05-20 returned -13.4% at 30 days. The pattern of multiple accumulations in rapid succession, combined with the stock's sustained decline from its 52-week peak and the company's ongoing unprofitability, suggests the filing warrants deeper investigation into the company's operational trajectory and whether this sustained buying pattern reflects a contrarian conviction or responds to other factors.

July 2025
2025-07-21 PETMED EXPRESS INC PETS
medium
Buy
17,565 shares
$56,735
Significance 4/10

Silvercape Investments (10% owner) buys 17,565 PETS shares at $3.23; stock now at $3.41, -48.3% from 52-week high.

Silvercape Investments, holding 2.36M shares of PETMED EXPRESS, purchased 17,565 additional shares at $3.23 on 2025-07-18, adding 0.7% to its stake. The company is unprofitable (full-year net income was negative, most recent quarter net income was $-707,000), trades at an elevated P/E of 170.50, and the stock is down 48.3% from its 52-week high, though it has recovered +5.2% over the past 30 days and +8.6% over 90 days. Notably, Silvercape has made four separate purchases at PETS in rapid succession (2025-05-20, 2025-07-01, 2025-07-02, and 2025-07-17), with only the May 20 purchase showing a measurable 30-day outcome of -13.4% — consistent with the insider's broader cross-ticker track record of -13.4% average 30-day returns on prior buys. This pattern of repeated purchases during a period of continued selling pressure and near-term negative returns warrants tracking to discern whether this represents a contrarian accumulation thesis or a sequence of poorly-timed entries.

2025-07-18 PETMED EXPRESS INC PETS
medium
Buy
31,701 shares
$99,858
Significance 4/10

10% owner Silvercape buys 31,701 PETS shares at $3.15; 4 consecutive buys in 2.5 weeks amid -49.8% drop from 52-week high

Silvercape Investments, a 10% holder, purchased 31,701 shares at $3.15 on 2025-07-17, expanding its position by +1.4% to 2,342,931 shares. This is the fourth consecutive open-market buy at PETS in 17 days (purchases on 2025-05-20, 2025-07-01, 2025-07-02, and 2025-07-17), all while the stock trades 49.8% below its 52-week high of $6.60. The company is unprofitable (net income of $-707,000 over the latest quarter) despite 9.4% annual revenue growth, with a stretched P/E of 165.50. Silvercape's cross-ticker open-market buy history shows an average 30-day return of -13.4%, and its single measurable same-ticker buy (2025-05-20) also declined 13.4% over 30 days. The pattern of repeated purchases into a depressed stock price warrants monitoring of the insider's conviction thesis versus realized outcomes.

2025-07-03 PETMED EXPRESS INC PETS
low
Buy
2,817 shares
$9,071
Significance 3/10

10% owner Silvercape Investments bought 2,817 shares of PETS at $3.22 on 2025-07-02, adding to holdings post-recent buying.

Silvercape Investments Ltd, holding 2,311,230 shares post-transaction (10% owner), purchased 2,817 shares at $3.22, continuing a pattern of modest accumulation—a buy on 2025-07-01 immediately preceded this transaction. However, the prior buy at this ticker on 2025-05-20 at $3.22 showed a -13.4% 30-day return, and the stock now trades -50.2% from its 52-week high and -16.7% over the past 30 days, suggesting deteriorating market conditions since the earlier purchase. PETS is unprofitable (full-year net income was negative, latest quarter net income $-707,000.00) despite +9.4% annual revenue growth, and carries an elevated P/E of 164.50. The small purchase size relative to holdings (+0.1%) does not signal material new conviction; rather, it reflects incremental positioning in a declining stock where the insider's prior recent transaction has not yet generated measurable returns.

2025-07-02 PETMED EXPRESS INC PETS
low
Buy
694 shares
$2,228
Significance 3/10

10% owner Silvercape Investments bought 694 shares of PETS at $3.21 on 2025-07-01; stock down -48.9% from 52-week high, company unprofitable.

Silvercape Investments, a 10% shareholder, purchased 694 shares at $3.21, a small absolute addition to its 2.31M share position. The timing coincides with a significant drawdown: PETS is trading -48.9% from its 52-week high of $6.60 and down -11.8% over the prior 30 days. The company's fundamentals remain challenged—it reported a net loss of -$707,000.00 in the latest quarter, operates with a P/E of 168.50, and generated annual revenue of $53.0M with only +9.4% year-over-year growth. Silvercape's own track record across tickers shows an average 30-day return of -13.4% on prior buys, and at this ticker specifically, a prior May buy returned -13.4% over 30 days, suggesting limited success timing market entries. The small size of this purchase (0.0% increase to holdings) and the absence of measurable outcomes on prior PETS transactions limit the strength of any signal this trade conveys.

May 2025
2025-05-22 PETMED EXPRESS INC PETS
medium
Buy
7,401 shares
$29,234
Significance 4/10

Silvercape Investments Ltd (10% owner) purchased 7,401 shares of PETS at $3.95 on 2025-05-20; stock -42.4% from 52-week high, company unprofitable.

Silvercape Investments Ltd, holding 2,307,719 shares (2.31M shares) post-transaction, acquired 7,401 shares at $3.95 during a period of significant stock weakness—the current price of $3.80 sits 42.4% below the 52-week high of $6.60. The company's fundamentals remain challenged, with net income of $-707,000.00 ($-707.0K) in the latest quarter and unprofitability in the full fiscal year despite 9.4% annual revenue growth to $53.0M. This modest purchase of 7,401 shares (+0.3% vs pre-transaction holdings) by a substantial shareholder adds modestly to an already-large position in a depressed valuation context, though the scale of the transaction relative to holdings and the company's profitability trajectory warrant monitoring of whether this reflects confidence in turnaround potential or routine portfolio management.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access